Dispatch Bio

Register to hear about our presentation, among others, at sitcancer.org/edu/2026-sprin…

Dispatch will participate in the 2026 @sitcancer Spring Scientific in Tucson, in which our CSO, Barbra Sasu, PhD, will present on how synthetic antigen strategies may enable universal immunotherapies across solid tumors. Looking forward to engaging with the IO community!

We were honored to receive the Emerging Company of the Year Award at the @LifeSciencesPA 2026 Annual Dinner & Showcase. This recognition reflects our team’s persistence and determination to advance new approaches designed to overcome the challenges of treating solid tumors.

This week, Dispatch leadership & co-founders shared our story with the MBC BioLabs community in SF to discuss how we’re advancing a first-in-class platform to overcome targeting and resistance challenges in treating solid tumors. Thanks for hosting!

Congrats to PICI Center Director Carl June, MD, named a Citizen of the Year by @PhilaCitizen. From CAR-T breakthroughs to co-launching @DispatchBio, a PICI portfolio company, Carl is pushing cancer innovation toward a future of universal cancer therapies.

At #AACRIO26, our co-founder & CPO will highlight our clinical-stage Flare platform. Flare uses a tumor-specific virus to paint a universal synthetic antigen on tumor cells–enabling precise T cell recognition while reshaping the tumor microenvironment to support immune activity.

The ECI Advancing Manufacture of Cell & Gene Therapies meeting reinforced the importance of product understanding & analytical rigor in scaling complex therapies–principles that align with how we aim to advance science & engineer a universal treatment across solid tumors.

Congrats to Carl June, MD, named a Citizen of the Year (Disruptor of the Year) by @PhilaCitizen. From pioneering CAR-T therapy to launching @DispatchBio—rooted in Philly’s "Cellicon Valley"—his research continues to push the boundaries of cancer treatment. thephiladelphiacitizen.org/meet-the-citiz…

We look forward to continuing this dialogue at the upcoming #IO360Summit, where Barbra will participate in discussions focused on advancing next-generation immuno-oncology strategies and translating scientific progress into clinical impact. Register here: reg.theconferenceforum.org/event/io360-20…

In a recent interview, our CSO, Barbra Sasu, shared insights on Dispatch’s novel approach to overcoming longstanding challenges in solid tumors, as well as insights from her extensive experience in drug discovery. Read the full interview here: theconferenceforum.org/editorial/comb…

A cancer diagnosis can turn a person’s world upside down. On #WorldCancerDay & in solidarity with patients, families, caregivers, & clinicians, we’ve turned our logo upside down. We share in this community’s commitment to working toward better treatment options & real hope.

View the full schedule here: ssl.linklings.net/conferences/ce…

Dispatch is participating in the ECI Advancing Manufacture of Cell & Gene Therapies meeting next week, presenting on how analytical rigor & product understanding can enable control strategies, overcome development challenges, and lead to accessible therapies for patients.

Our Executive Director of Virology Research will join academic and industry leaders at @WistarInst’s Philadelphia Drug Discovery Forum to discuss emerging drug discovery strategies. We look forward to the insights to come that could help accelerate new cancer treatments.

Congratulations to our CEO, Sabah Öney, on his appointment to the Board of Directors at @FredHutch. We look forward to the progress they will continue to make to translate discoveries into cures. Read more: fredhutch.org/en/news/releas…

Read the full release here. dispatchbio.com/news/dispatch-…

Today, we announced a clinical collaboration with @CARsgen_Ther to conduct a Ph 1 trial in China, planned to begin in 2026. This represents a critical step forward in bringing our immunotherapy approach to patients in need, and CARsgen is an ideal partner.

Read the full release here. dispatchbio.com/news/dispatch-…

We're pleased to announce the FDA clearance of the IND for DISP-10, enabling us to initiate a Ph1 clinical study in patients with solid tumors. Designed for broad applicability, DISP-10 has the potential to expand into multiple solid tumor indications.

Learn more here: secure.qgiv.com/for/climbforac…

Dispatch supports #ClimbForACause with Brad Watts as he takes on the Timmerman Traverse to raise funds for @DamonRunyonFdn. Our co-founder & CPO will join a cell & gene therapy panel focused on translating innovation to patient impact.